Intercontinental comparison of women with breast cancer treated by oncologists in Europe, Asia, and Latin America: a retrospective study of 99,571 patients
- PMID: 36920565
- PMCID: PMC10374727
- DOI: 10.1007/s00432-023-04681-7
Intercontinental comparison of women with breast cancer treated by oncologists in Europe, Asia, and Latin America: a retrospective study of 99,571 patients
Abstract
Purpose: The aim of the study was to evaluate the baseline data of women with breast cancer (BC) undergoing treatment in an intercontinental comparison.
Methods: This study included 99,571 women with BC from Europe (70,834), Asia (18,208), and Latin America (10,529) enrolled between 2017 and 2021, based on data from IQVIA's Oncology Dynamics database. This source is supplied with information by means of a cross-sectional partially retrospective survey collecting anonymized data on inpatients and outpatients treated by a representative panel of oncologists. A multivariable logistic regression model was used to investigate the probability of metastases.
Results: The data available in Asia (98%) and Latin America (100%) were hospital data, while in Europe, patients were treated both in hospitals and in office-based practices (62%, 38%). The mean age in Asia and Latin America (57 ± 13) was lower than in Europe (61 ± 13; p < 0.001). Lobular BC was diagnosed twice as often in Europe compared to Asia and Latin America (15.2%, 9.8%, 8.0%). The number of patients with metastasized hormone receptor-positive (HR +) BC was significantly higher in Europe and Latin America than in Asia (76%, 68%; p < 0.001). The highest number of women with metastasized BC was reported in Europe (26% compared to 14% and 20%, respectively, in Asia and Latin America). Across the continents, the percentage of women with BC who experienced metastases was 51-61% for bone, 30-39% for lung and 25-32% for liver, followed by 3-6% for skin and 3% for brain.
Conclusion: Women with BC treated in Europe tend to be significantly older and more likely to develop metastases than women in Asia and Latin America, except for lung metastases.
Keywords: Breast cancer; Intercontinental comparison; Metastatic disease; Oncology; Retrospective study.
© 2023. The Author(s).
Conflict of interest statement
None.
Figures
Similar articles
-
Comparison of Two Modern Survival Prediction Tools, SORG-MLA and METSSS, in Patients With Symptomatic Long-bone Metastases Who Underwent Local Treatment With Surgery Followed by Radiotherapy and With Radiotherapy Alone.Clin Orthop Relat Res. 2024 Dec 1;482(12):2193-2208. doi: 10.1097/CORR.0000000000003185. Epub 2024 Jul 23. Clin Orthop Relat Res. 2024. PMID: 39051924
-
MS and Disability Progression in Latin America, Africa, Asia and the Middle East: A Systematic Review.Mult Scler Relat Disord. 2021 Jun;51:102885. doi: 10.1016/j.msard.2021.102885. Epub 2021 Mar 9. Mult Scler Relat Disord. 2021. PMID: 33773273
-
Bisphosphonates and other bone agents for breast cancer.Cochrane Database Syst Rev. 2017 Oct 30;10(10):CD003474. doi: 10.1002/14651858.CD003474.pub4. Cochrane Database Syst Rev. 2017. PMID: 29082518 Free PMC article.
-
Cost-effectiveness of using prognostic information to select women with breast cancer for adjuvant systemic therapy.Health Technol Assess. 2006 Sep;10(34):iii-iv, ix-xi, 1-204. doi: 10.3310/hta10340. Health Technol Assess. 2006. PMID: 16959170
-
A systematic review of evidence on malignant spinal metastases: natural history and technologies for identifying patients at high risk of vertebral fracture and spinal cord compression.Health Technol Assess. 2013 Sep;17(42):1-274. doi: 10.3310/hta17420. Health Technol Assess. 2013. PMID: 24070110 Free PMC article.
Cited by
-
Therapy delay due to COVID-19 pandemic among European women with breast cancer: prevalence and associated factors.J Cancer Res Clin Oncol. 2023 Oct;149(13):11749-11757. doi: 10.1007/s00432-023-05065-7. Epub 2023 Jul 5. J Cancer Res Clin Oncol. 2023. PMID: 37405476 Free PMC article.
-
Reporting on invasive lobular breast cancer in clinical trials: a systematic review.NPJ Breast Cancer. 2024 Mar 20;10(1):23. doi: 10.1038/s41523-024-00627-5. NPJ Breast Cancer. 2024. PMID: 38509112 Free PMC article. Review.
-
HIGH-RISK HISTOPATHOLOGICAL FEATURES OF RETINOBLASTOMA FOLLOWING PRIMARY ENUCLEATION: A Global Study Of 1,426 Patients From 5 Continents.Retina. 2024 Dec 1;44(12):2105-2115. doi: 10.1097/IAE.0000000000004250. Epub 2024 Nov 12. Retina. 2024. PMID: 39151183 Free PMC article.
-
Leveraging MRI radiomics signature for predicting the diagnosis of CXCL9 in breast cancer.Heliyon. 2024 Sep 28;10(19):e38640. doi: 10.1016/j.heliyon.2024.e38640. eCollection 2024 Oct 15. Heliyon. 2024. PMID: 39430466 Free PMC article.
-
Surgery paradigm for locally advanced breast cancer following neoadjuvant systemic therapy.Front Surg. 2024 Sep 6;11:1410127. doi: 10.3389/fsurg.2024.1410127. eCollection 2024. Front Surg. 2024. PMID: 39308852 Free PMC article. Review.
References
-
- Abdoli G, Bottai M, Sandelin K, Moradi T (2017) Breast cancer diagnosis and mortality by tumor stage and migration background in a nationwide cohort study in Sweden. Breast 31:57–65 - PubMed
-
- Allemani C, Sant M, Weir HK, Richardson LC, Baili P, Storm H, Siesling S, Torrella-Ramos A, Voogd AC, Aareleid T, Ardanaz E, Berrino F, Bielska-Lasota M, Bolick S, Cirilli C, Colonna M, Contiero P, Cress R, Crocetti E, Fulton JP, Grosclaude P, Hakulinen T, Izarzugaza MI, Malmström P, Peignaux K, Primic-Žakelj M, Rachtan J, Safaei Diba C, Sánchez MJ, Schymura MJ, Shen T, Traina A, Tryggvadottir L, Tumino R, Velten M, Vercelli M, Wolf HJ, Woronoff AS, Wu X, Coleman MP (2013) Breast cancer survival in the US and Europe: a CONCORD high-resolution study. Int J Cancer 132(5):1170–1181 - PMC - PubMed
-
- Alymova S, Kostev K, Casey V, Schmidt N, Kalder M, Roderburg C, Friedersdorf N (2022) Evaluation of the representativeness of the German oncology dynamics dataset. Int J Clin Pharmacol Ther 60(5):207–216 - PubMed
MeSH terms
LinkOut - more resources
Full Text Sources
Medical